BioNTech is doing something similar. Their approach (and likely also Moderna's approach) works by first identifying mutations in protein coding genes in the cancer cells. Then, they target the resulting mutated protein (that is distinct from the same protein in non-cancer calls) with their vaccines.
BioNTech is doing something similar. Their approach (and likely also Moderna's approach) works by first identifying mutations in protein coding genes in the cancer cells. Then, they target the resulting mutated protein (that is distinct from the same protein in non-cancer calls) with their vaccines.